In this Q&A, Michelle Hall, Vice President of Marketing at Mikart, shares how the CDMO is moving beyond generic manufacturing to support customers end-to-end, from non-GMP preclinical work to full-scale GMP commercial volumes, with a recently expanded range of capabilities, to bring their candidates to the clinic and the market.
.svg)
